Zydus Lifesciences Share Price
₹988.45 -16 (-1.59%)
05 Nov, 2024 17:21
Start SIP in
ZYDUSLIFE
Performance
- Low
- ₹970
- High
- ₹1,005
- 52 Week Low
- ₹579
- 52 Week High
- ₹1,324
- Open Price₹999
- Previous Close₹1,004
- Volume1,897,494
Investment Returns
- Over 1 Month -6.52%
- Over 3 Month -20.92%
- Over 6 Month -0.9%
- Over 1 Year + 69.01%
Smart Investing Starts Here Start SIP with Zydus Lifesciences for Steady Growth!
Zydus Lifesciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 23
- PEG Ratio
- 0.3
- Market Cap Cr
- 99,461
- P/B Ratio
- 4.5
- Average True Range
- 24.43
- EPS
- 34.2
- Dividend Yield
- 0.3
- MACD Signal
- -23.32
- RSI
- 40.03
- MFI
- 36.2
Zydus Lifesciences Financial
| Indicator | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 |
|---|---|---|---|---|---|
| Net Sales/Income from operations | 4,035.40 | 3,172.60 | 2,371.30 | 2,159.30 | 2,955.70 |
| Total Income From Operations | 4,160.20 | 3,332.40 | 2,371.30 | 2,159.30 | 2,955.70 |
| P/L Before Interest, Excpt. Items & Tax | 2,348.90 | 1,799.70 | 678.20 | 1,059.00 | 1,102.20 |
| P/L Before Exceptional Items & Tax | 2,233.50 | 1,693.50 | 574.30 | 968.10 | 1,012.50 |
| P/L After Tax from Ordinary Activities | 1,700.80 | 1,405.20 | 450.40 | 805.00 | 780.90 |
| Net Profit/Loss For the Period | 1,700.80 | 1,405.20 | 450.40 | 805.00 | 780.90 |
Zydus Lifesciences Technicals
EMA & SMA
-
- Bullish Moving Average 0
-
- Bearish Moving Average 16
- 20 Day
- ₹1,019.56
- 50 Day
- ₹1,058.01
- 100 Day
- ₹1,066.20
- 200 Day
- ₹1,000.82
Resistance and Support
- R3 1,029.52
- R2 1,020.58
- R1 1,012.52
- S1 995.52
- S2 986.58
- S3 978.52
Zydus Lifesciences Corporate Actions - Bonus, Splits, Dividends
Zydus Lifesciences F&O
About Zydus Lifesciences
Zydus Lifesciences Limited (Zydus) is one of India’s leading pharmaceutical companies, engaged in the formulation and marketing of pharmaceutical products. Zydus Group has a leadership position in several segments in its portfolio with brands that are market leaders in their respective categories.
The Group has a strong presence across therapeutic segments including pain management, cardiovascular diseases, urology and anti-infectives. It also offers over-the-counter healthcare products. It sells medicines through retail pharmacies, hospitals, and clinics to customers all over India and exports to various countries worldwide.
The Company is organized into three business verticals: Pharmaceuticals, Active Ingredients and Contract Manufacturing Services (CMS). It manufactures active ingredients for use in formulations manufactured by other pharmaceutical companies; distributes finished formulations; provides contract manufacturing services for branded drugs, and markets finished formulations under its brand names.
Business Verticals
Zydus Lifesciences has three business divisions. The largest division is pharmaceuticals, which includes oral solid dosage and injectables. The second division is hospital equipment and supplies. Finally, there is a medical education division that includes training programs for medical professionals in both rural and urban areas as well as retail stores selling over-the-counter products to consumers.
In addition to these divisions, Zydus Lifesciences provides consulting services for companies looking to enter or expand their presence in India. These services include regulatory and market access assistance, drug registration services, strategic marketing support and distribution channel optimization.
Milestones
1995 - Cadila Healthcare Ltd, the flagship company of the Zydus Cadila Group, was founded.
1996 - It went public in July. They also formed a strategic alliance with Gulin Pharma of China and launched Falcigo, an anti-malarial segment, in India.
2000 - In May, the company acquired Recon Ltd's formulation business, to strengthen its position in the southern market.
2001 - Acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector at the time. The same year they formed a joint venture with US-based Onconova for collaborative research in the field of Oncogenomics.
2002 - In April, the company acquired Banyan Chemicals, a Vadodara-based company registered with the US Food and Drug Administration.
2003 - Zydus Group decided to merge German Remedies Ltd and Recon Healthcare Ltd with Cadila Healthcare Ltd
2004 - In November, the company formed a strategic alliance with the Zambon Group in Italy to explore new opportunities in contract manufacturing. The same year, the company signed a long-term strategic agreement with Boehringer Ingelheim India Ltd, a wholly-owned subsidiary of Boehringer Ingelheim (BI), to manufacture and market BI's products in India.
2005 - The company formed a strategic alliance with Mallinckrodt Pharmaceuticals Generics, a Tyco Healthcare business unit, to market the company's product under a joint label. In the same year, the company formed a 50:50 joint venture with Australia's Mayne Pharma to produce generic injectable cytotoxic (anti-cancer) medicines as well as active pharmaceutical ingredients (API) for global markets.
2005-06 - During this fiscal year, the company formed a 50:50 joint venture with one of India's leading biotech companies, Bharat Serums and Vaccines Ltd (BSV), to develop, manufacture, and market a non-infringing and proprietary Novel Drug Delivery System (NDDS) of an approved anticancer product for global markets.
2006-07 - During this fiscal year, the company entered into a share purchase agreement to acquire a 97.95 per cent stake in Liva Healthcare Ltd, which manufactures and markets Formulations. They also built a brand-new green field facility for Solid Oral Dosage. They also built a Lyophilisation facility at the Moraiya plant with an annual capacity of 7.5 million dosages to serve both the Indian and international markets.
2007-08 - During this fiscal year, the company restructured its formulation division, Alidac, and launched two new subdivisions, Corza and Fortiza.
- NSE Symbol
- ZYDUSLIFE
- BSE Symbol
- 532321
- Managing Director
- Dr. Sharvil P Patel
- ISIN
- INE010B01027
Zydus Lifesciences FAQs
Zydus Lifesciences share price is ₹988 As on 05 November, 2024 | 17:07
The Market Cap of Zydus Lifesciences is ₹99461.2 Cr As on 05 November, 2024 | 17:07
The P/E ratio of Zydus Lifesciences is 23 As on 05 November, 2024 | 17:07
The PB ratio of Zydus Lifesciences is 4.5 As on 05 November, 2024 | 17:07
Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20 crores in FY22
Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.
The company's shares can be bought online opening a demat account with 5paisa and verifying the KYC documents. You can also open demat account via our mobile app.